Octreotide acetate in dominant cystoid macular dystrophy.
SourceEuropean Journal of Ophthalmology, 18, 1, (2008), pp. 99-103
Article / Letter to editor
Display more detailsDisplay less details
European Journal of Ophthalmology
SubjectIGMD 6: Hormonal regulation; NCEBP 2: Evaluation of complex medical interventions; UMCN 3.3: Neurosensory disorders; UMCN 5.2: Endocrinology and reproduction
PURPOSE: Dominant cystoid macular degeneration (DCMD) is an autosomal dominant trait of cystoid macular edema with poor visual prognosis. Until now, no efficient treatments for DCMD have been reported. The authors evaluated a somatostatin-analogue (octreotide acetate) as treatment for DCMD. METHODS: The authors treated four patients with early DCMD by intramuscular longacting octreotide acetate, 20 mg every 4 weeks for 1 year. In addition to general ophthalmologic examination the authors performed fluorescein angiography (FA) before and after treatment. RESULTS: Seven out of eight eyes showed improvement on FA and stabilization of visual acuity. CONCLUSIONS: Somatostatin-analogues may reduce cystoid edema in DCMD and may thus prevent disease-related visual loss.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.